Alyeska Investment Group
GANX icon

Alyeska Investment Group’s Gain Therapeutics GANX Stock Holding History

Alyeska Investment Group’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-450,000
Closed -$576K – 591
2024
Q2 		$576K Buy
+450,000
New +$1.17M ﹤0.01% 494

Other funds holding GANX

GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's GANX Position: Q3 2024 in Review

Alyeska Investment Group sold out of Gain Therapeutics (GANX) in Q3 2024, closing a stake of 450,000 shares — an estimated $576K sold.

Alyeska Investment Group first reported a position in GANX in Q2 2024 and held it in 1 quarter. The position peaked at $576K in Q2 2024. 19 funds tracked by Wall St. Rank hold GANX as of Q3 2024.

  • Alyeska Investment Group reported no remaining Gain Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 450,000 Gain Therapeutics shares in Q3 2024, an estimated $576K.
  • Alyeska Investment Group first reported a position in Gain Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alyeska Investment Group's Gain Therapeutics position peaked at $576K in Q2 2024.
  • 19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.